Loading
Latest filing published 31 Mar 2026 for Marinomed Biotech AG, €21k.
Not enough buy signals with a settled T+90 horizon to measure a track record yet.
Karl Mahler, listed as chief executive, appears in our data through filings on Marinomed Biotech AG shares, published by FMA (OeKB OAM). The record holds 3 filings, for trades running from 8 January 2025 to 31 March 2026.
Every open-market trade on record is a purchase: 1 purchase worth €21k, and no sale. Buying on the open market means paying the going price with one's own funds, a different act from receiving shares as pay.
On 31 March 2026 came the latest disclosure, a transaction for €21k in Marinomed Biotech AG. The most recent open-market purchase was published on 20 January 2025, 642 days ago. Publication is fast: at least half of the trades appear on FMA (OeKB OAM) on the same day. Under the Market Abuse Regulation, managers have three business days to notify their trades. This summary is built from FMA (OeKB OAM) disclosures alone and does not predict where the share price will go.
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
3 of 3 declarations